Karen Mayne

Prospective Molecular Marker Analyses of <i>EGFR</i> and <i>KRAS</i> From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non–Small-Cell Lung Cancer

Wolfram Brugger, Nadja Triller, Maria Błasińska-Morawiec et al. · Journal of Clinical Oncology · 2011 · 279 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group

M Marty, Francesco Cognetti, D Maraninchi et al. · Journal of Clinical Oncology · 2005 · 94 citations · Full text

Medicine, Oncology, Pharmacology +17

Trastuzumab plus capecitabine with or without pertuzumab in patients with HER2-positive MBC whose disease has progressed during or following trastuzumab-based therapy for first-line metastatic disease: A multicenter, randomized, two-arm, phase II study (PHEREXA).

Montserrat Muñoz-Mateu, Ander Urruticoechea, Robert Šeparović et al. · Journal of Clinical Oncology · 2011 · 12 citations

Medicine, Pharmacology, Pharmacotherapy +14